PharmaCyte Biotech Inc. Common Stock (PMCB)

FairStock Score: 64/100 — STEADY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

As a value investor, I start with the business and the price. PharmaCyte is a two-employee biotech developing live-cell encapsulation for cancer. I see no reported revenue in the filed figures. In fiscal 2026, the year ended 2026-04-30, it reported a net loss of $19.4 million and diluted EPS of $-2.77. That followed fiscal 2025, the year ended 2025-04-30, when it reported net income of $30.7 million and diluted EPS of $3.19. But the latest fiscal Q1 2027, the quarter ended 2026-07-31, showed another net loss of $5.1 million and diluted EPS of $-0.54. FairStock computes the Lynch category as TURNAROUND - loss in the latest year after earlier profits. The company may have a proprietary Cell-in-a-Box platform, but a moat must be proven by pricing power, recurring revenue, and durable returns. Here revenue is absent, ROE is -43.99%, ROCE is -8.35%, and trailing free cash flow is -$3.9 million. FairStock calculates an FCF yield of -103.1% of market cap, which tells me cash burn is enormous relative to the $3.8 million market cap at the 2026-10-13 close. The FairStock Piotroski F-Score is 1/9 and Altman Z-Score is -2.85, both warning signs. On the other hand, FairStock's P/B of 0.14 at that close means the market values the equity far below book value. Graham would ask whether those assets are real and whether they will be consumed by losses. With no revenue, negative cash flow, and a tiny equity base, this is a speculation on future therapy approval, not a proven compounding business. Cheap on assets, expensive on uncertainty.

In plain English: PharmaCyte Biotech is a very small healthcare company with two employees that is trying to develop cell-based cancer treatments. It has no reported revenue and has recently been losing a lot of money, so the business looks weak and unproven. The stock trades for very little compared with the value of its stated assets, but because it is burning cash, that cheapness is not the same as safety.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q1 2027 10-Q (period ended 2026-07-31) · fiscal Q3 2026 10-Q (period ended 2026-01-31) · fiscal Q2 2026 10-Q (period ended 2025-10-31) · fiscal Q1 2026 10-Q (period ended 2025-07-31) · FY2026 10-K (period ended 2026-04-30) · FY2025 10-K (period ended 2025-04-30) · FY2024 10-K (period ended 2024-04-30)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer